Urologix Overview

Urologix, LLC. develops, manufactures and markets minimally invasive office-based BPH therapies for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH).  Since the introduction of office-based therapies nearly 20 years ago, these two technologies have consistently demonstrated safe, efficacious and durable results for patients. Urologix, the market leader and most trusted name in minimally invasive BPH therapies, is proud to offer Cooled ThermoTherapy™ (CTT) and Prostiva® RF Therapy (Prostiva).  These two technologies provide Urologists the versatility to treat the majority of prostate anatomies in the office, and provide clinically significant symptom score and flow rate improvement without need for re-treatment in over 90% and 86% of patients, respectively through 5 years.1,2

Watch the Urologix “Our Story” video to learn more about the history and culture of our company.

Urologix has a two-decade track record of providing long-lasting BPH relief to patients who desire an alternative to chronic medication.

“I have extensively used the various microwave-related prostate therapy machines (TherMatrx, Prolieve, Urologix), not only has the Urologix unit provided the longest duration of symptom improvement, it is the only machine that has left men with actual cavitation defects when viewed cystoscopically months after the treatment.” – Michael Lazar, MD
“Minimally invasive therapies are significantly more effective for relief of lower urinary tract symptoms than pharmacologic therapy as demonstrated in randomized clinical trials. Moreover, durability for both Cooled ThermoTherapy and Prostiva are well documented in the literature. Since 1988, I have treated more than 800 patients with Cooled ThermoTherapy and the retreatment rate for my patients after 14 years is only 14%. I believe that minimally invasive therapies for patients with symptomatic BPH should be the primary therapy because they provide more significant symptom relief and have durable results.” – Robert G. Pugach, MD

Our Vision

Improving quality of life, one patient at a time, as the urologist’s trusted partner to realize the full potential of in-office, evidence-based technologies.

Our Mission

We develop and deliver innovative in-office technologies, best-in-class training and excellent customer service, with a focus on BPH leadership.  Success is superior patient outcomes, physician satisfaction and healthcare value.

Our Guiding Principles

  • Patient safety is primary
  • Improve the quality of life for our patients by providing safe, durable, effective and high quality products
  • Invest in talent acquisition, development, and retention
  • Exhibit a culture of quality, accountability, integrity, and empowerment
  • Demonstrate excellence in mission focus, communication and collaboration
  • Be resourceful, responsive and reliable
  • Deliver a fair return on shareholder investment through thoughtful business management
  • Improve continuously

1Mynderse, L., et al, 5 year Results of a Multi-Center Trial of a New Generation Cooled TUMT for BPH, Journal of Urology, May 2001 2Hill, B., et al Transurethreal Needle Ablation vs TURP for the Treatment of Symptomatic BPH: 5 Year Results of a Prospective, Randomized, Multicenter Clinical Trial, Journal of Urology Vol 171, 2336-2340, June 2004